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Abstract  
A 52-year-old female with a history of poorly controlled resistant hypertension was admitted to our hospital with severe hypertension. She had a 
history of fatigue and intermittent episodes of palpitations. Laboratory evaluation was significant for elevated 24-h urinary catecholamine levels 
(3,5 times the upper normal levels). This case was presenting with a clinical and biochemical picture indistinguishable from that of 
pheochromocytoma. However, neither computed tomography nor meta-iodo-benzyl-guanidine scintigraphy detected any catecholamine-producing 
tumor in or outside the adrenal glands. Our patient was screened with full polysomnography because of heavy snoring, daytime somnolence and 
obesity. It revealed severe obstructive sleep apnea syndrome. After three months of continuous positive airway pressure therapy, the patient 
experienced resolution of his presenting symptoms, improved blood pressure control and normalization of his urinary catecholamine levels. This 
case highlights sleep disordered breathing as a potentially reversible cause of pseudo-pheochromocytoma. 
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The obstructive sleep apnea syndrome (OSAS) has a well-
documented association with increase cardiovascular morbidity and 
mortality [1].The patients with OSAS have a high prevalence of 
hypertension (HTA) and the OSAS may present similar to a pseudo-
pheochromocyto¬ma. Indeed, this syndrome can elevate 
cat¬echolamine secretion and increased sympathetic activity which 
may mimic the biochemical profile of pheochromocyto¬ma 
[2].Treatment of OSAS may normalize the effects of this 
sympa¬thetic overdrive and resolve excessive catecholamine 
secretion. In this article, we report a case with pseudo-
pheochromocytoma caused by OSAS; a common medical condition 
which is less recognized as a cause of raised catecholamines. 
  
  
Patient and observation 
 
A 52-year-old female was admitted in the department of 
endocrinology with severe headache, dizziness, and visual problems. 
She had been treated for hypertension diagnosed eight months ago. 
She was taking Acebutolol 200 mg /day, amlodipine 10 mg/day, and 
a combination of angiotensin-conversion enzyme inhibitor (Captopril 
300 mg daily), Indapamide 1,5 mg daily but experienced several 
hypertension peaks and hypotension. She adhered to treatment, 
was neither using traditional herbal medication nor illicit drugs, had 
no known family history of endocrine disorders and she did not 
smoke. At admission, his blood pressure was 200/120 mm of Hg. 
His body mass index was 31 kg/m². Physical examination was 
unremarkable. Fundoscopic examination of the eye revealed 
hypertensive retinopathy stage 2 of Kirkendall classification. 
Electrocardiography and echocardiography found slight left 
ventricular hypertrophy with normal cardiac output. Laboratory tests 
found an hypokalemia= 3,5 mmol/l, an elevated creatinine level at 
120µmol/l with normal fasting glycemia and lipid profile. Laboratory 
evaluation was significant for elevated 24-h urinary catecholamine 
levels (3,5 times the upper normal levels). Ultrasound and 
Computed Tomography-scan showed kidneys with normal size, 
good cortical index, and normal vessels. In addition, neither 
computed tomography nor meta-iodo-benzyl-guanidine (MIBG) 
scintigraphy detected any catecholamine-producing tumor in or 
outside the adrenal glands. On further questioning, she admitted to 
a long history of loud snoring and day time somnolence. His 
Epworth sleepiness score (ESS) was 16, suggesting excessive 
daytime sleepiness (normal <10). Subsequently, a home-based 
overnight polysomnography showed evidence of severe OSA with an 
apnoea hypopnoea index (AHI) of 30 events/hour (normal <5). We 
stopped slowly Acebutolol and Indapamide, continued the 
angiotensin-conversion enzyme inhibitor and Calcium channel 
blockers and added Prazosine 5 mg daily to patient´s treatment. 
Following 3 weeks of overnight continuous positive airway pressure 
(CPAP) therapy, the patient recorded daily self-measured blood 
pressure at home with a semi-automatic sphygmomanometer. All 
blood pressure measures were under 130/80 mm of Hg like the one 
measured during consultation. Three months later, a new 
fundoscopic eye examination realized, showed regression of 
retinopathy to stage 1 and his urinary cathecolamine levels 
normalized. She had felt better without any symptom, we reduced 
captopril to 200 mg /day and stopped prazosine and amlodipine to 
prevent hypotension episodes and she had a stable blood pressure 






OSAS is characterized by upper airway occlusion and recurrent 
cessation of respiratory flow during sleep. Hypoxia ensues, followed 
by repeated arousal episodes in an attempt to restore airway 
patency. Patients complain of disturbed sleep and daytime 
somnolence, and relatives may give a long history of loud snoring. 
Diagnosis is made by overnight monitoring of arterial oxygenation, 
chest wall movement, and airflow, proceeding to full 
polysomnography in equivocal cases. This syndrome has a well-
documented association with increased cardiovascular morbidity and 
mortality [1] and has been shown to be an independent risk factor 
for the development of systemic hypertension [3]. Since the 1980s 
it has been thought that sympathetic activity is up-regulated in 
patients with sleep-disordered breathing. Twenty-four-hour urinary 
catecholamine levels were initially found to be increased in patients 
with untreated sleep apnea compared with those with narcolepsy 
[1,4]. Evidence is accumulating to suggest a role for sympathetic 
overactivity in the pathophysiology of these observations [5]. 
Indeed a small cohort of male patients with severe sleep apnea and 
elevated urinary catecholamine levels was found to lose the normal 
diurnal variation in sympathetic excretion, suggesting increased 
nocturnal sympathetic activity. OSAS, however, is not the only cause 
of pseudo-pheochromocytoma as they could be showed in other 
causes, notably physiological stress, antipsychotic drugs [6], anti-
parkinson drugs, tricyclic antidepressants and cocaine use. Panic 
attack, alcohol withdrawal and carcinoid syndromes are other 
situations that can explain pseudo-pheochromocytoma. None of 
these conditions were found in our patient who was previously 
healthy without any medication and denied any alcohol or illicit drug 
abuse. Other causes of secondary hypertension such as primary 
hyperaldosteronism, hyperthyroidism, hypercorticism, and endocrine 
neoplasms were excluded by hormonal explorations. In addition, 
mechanisms by which chemoreflex dysfunction may contribute to 
chronically elevated sympathetic tone and ultimately hypertension 
are discussed [7]. In one series, Hoy et al described 5 pa¬tients in 
whom no tumors were identified, and primary treatment for OSA 
normalized both clinical features and catecholamine excess [8]. 
These and similar reports strengthen the link between OSA and 
elevated sympathetic activity. While the exact mecha¬nism of this 
association is unknown, hypoxia-induced endothe¬lial dysfunction 
and oxidative stresses are thought to contribute. Further, repetitive 
arousals in response to anoxic/hypoxic epi¬sodes can lead to 
increased urinary catecholamine and meta¬nephrine levels [9]. 
Nasal CPAP therapy can reduce this increased sympathetic tone by 
preventing upper airway closure and mitigating repetitive arousals, 
as evidenced by normalization of sympathetic mark-ers following 
treatment. Further, CPAP has been shown to de¬crease parameters 
of sympathetic tone and decrease day and nighttime blood pressure 
recordings [9]. Nasal CPAP therapy is recommended not only to 
improve hypertension and catecholamine hypersecretion but also to 
distinguish the condition from pheochromocytoma. Finally this case 
represents a patient with undiscovered OSAS and dif¬ficult to 
control hypertension, with clinical and biochemical evidence of 
increased sympathetic activity mimicking a pheo¬chromocytoma. 
When imaging fails to reveal the presence of a catecholamine 
secreting tumor, a diagnosis of OSAS induced pseudo-
pheochromocytoma should be considered. Recognizing this 
association is important, as primary treatment for OSAS may lead to 
a resolution of symptoms and normalization of urinary 
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Conclusion 
 
Finally this case represents a patient with untreated OSAS and 
dif¬ficult to control HTA, with clinical and biochemical evidence of 
increased sympathetic activity mimicking a pheo-chromocytoma. 
Nasal CPAP therapy allows improvement of hypertension with 
catecholamine hypersecretion and distinction of this condition from 
pheochromocytoma. We suggest that a diagnosis of OSAS should be 
considered in patients with clinical and biochemical evidence of 
catecholamine excess in whom a catecholamine producing tumor 
cannot be identified. Recognizing this association is important, as 
primary treatment for OSAS may lead to a resolution of symptoms 
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